An update on the use of ophthalmic ketorolac tromethamine 0.4%

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.1, 2006-01, pp. : 99-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis

By Schechter Barry A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 4, 2008-04 ,pp. : 507-511

Informa Healthcare

Access to resources Recommend Favorite

Ketorolac 0.45% Ophthalmic Solution

By McCormack Paul L.

Drugs & Aging, Vol. 28, Iss. 7, 2011-07 ,pp. : 583-589

Adis International

Access to resources Recommend Favorite

Formulation and Optimization of a Sustained-Release Tablet of Ketorolac Tromethamine

By Vatsaraj Neha Zia Hossein Needham Thomas

Drug Delivery, Vol. 9, Iss. 3, 2002-07 ,pp. : 153-159

Informa Healthcare

Access to resources Recommend Favorite

Influence of Ultrasound on the Percutaneous Absorption of Ketorolac Tromethamine In Vitro Across Rat Skin

By Tiwari Sandip Pai Raveendra Udupa N.

Drug Delivery, Vol. 11, Iss. 1, 2004-01 ,pp. : 47-51

Informa Healthcare

Access to resources Recommend Favorite

Formulation, Characterization, and Evaluation of Ketorolac Tromethamine-Loaded Biodegradable Microspheres

By Sinha Vivek Trehan Aman

Drug Delivery, Vol. 12, Iss. 3, 2005-05 ,pp. : 133-139

Informa Healthcare

Access to resources Recommend Favorite